FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024667104> ?p ?o ?g. }

• W2024667104 abstract "Prevention of central nervous system (CNS) leukemia by early introduction of therapy to this sanctuary site is an essential component of modern treatment strategy for acute lymphoblastic leukemia (ALL). However, the optimal form of preventive CNS therapy remains debatable.To address this issue, we evaluated the efficacy of CNS preventive therapy for 572 children with ALL who achieved complete remission in the Children's Cancer and Leukemia Study Group (CCLSG) ALL874 (1987-1990) and ALL911 (1991-1993) studies. They received risk-directed therapy based on age and leukocyte count. In the ALL 874 study, the non-high-risk (low-risk [LR] + intermediate risk [IR]) patients were randomly assigned to the conventional cranial irradiation (CRT) regimen (L874A and I874A) and the high-dose methotrexate (HDMTX) regimen without CRT (L874B and I874B). The former patients received 18-Gy CRT plus 3 doses of intrathecal (i.t.) MTX and the latter patients received 3 courses of HDMTX at 2 g/m2 plus 13 doses of ITMTX (L874B) or 4 courses of HDMTX at 4.5 g/m2 plus 1 dose of ITMTX (I874B).The 7-year probabilities (+/- SE) of CNS relapse-free survival were 97.3% +/- 2.6% (L874A, n = 41) vs. 90.3% +/- 5.3% (L874B, n = 39) (P = 0.25) in the LR patients, and 100% (I874A, n = 55) vs. 78.5% +/- 6.5% (I874B, n = 54) (P = 0.002) in the IR patients. The corresponding disease-free survival (DFS) rates were 79.4% +/- 6.5% vs. 74.4% +/- 7.3% (P = 0.62) in the LR group and 63.3% +/- 6.8% vs. 58.3% +/- 7.2% (P = 0.66) in the IR group. Thus, the HDMTX regimen could not provide better protection of CNS relapse as compared with the CRT regimen, although their overall efficacy was not significantly different. In the ALL 911 study, intensive systemic chemotherapy with extended i,t, injections of MTX plus cytarabine achieved a high CNS relapse-free survival (98% +/- 1.9% at 7 years) and a favorable DFS (85.5% +/- 5% at 7 years) in the IR patients. The patients in the high-risk (HR) group in both ALL874 and ALL911 studies received the 18-Gy or 24-Gy CRT with intensive systemic chemotherapy. Their 7-year probabilities of CNS relapse-free survival ranged from 88% to 95%, among which the T-ALL patients had a risk of CNS leukemia, which was 3-4 times higher compared with B-precursor ALL patients.These results indicate that long-term intrathecal CNS prophylaxis as well as appropriate systemic therapy for the non-high-risk patients can provide protection against CNS relapse equivalent to that provided by cranial irradiation." @default.
• W2024667104 created "2016-06-24" @default.
• W2024667104 creator A5006642512 @default.
• W2024667104 creator A5007689159 @default.
• W2024667104 creator A5009641229 @default.
• W2024667104 creator A5013300560 @default.
• W2024667104 creator A5016860157 @default.
• W2024667104 creator A5017179381 @default.
• W2024667104 creator A5019608958 @default.
• W2024667104 creator A5027751015 @default.
• W2024667104 creator A5029680324 @default.
• W2024667104 creator A5030491895 @default.
• W2024667104 creator A5031445323 @default.
• W2024667104 creator A5033607211 @default.
• W2024667104 creator A5035749444 @default.
• W2024667104 creator A5044016093 @default.
• W2024667104 creator A5048912989 @default.
• W2024667104 creator A5056441277 @default.
• W2024667104 creator A5062333360 @default.
• W2024667104 creator A5063523753 @default.
• W2024667104 creator A5064262008 @default.
• W2024667104 creator A5067407925 @default.
• W2024667104 creator A5069503102 @default.
• W2024667104 creator A5074414195 @default.
• W2024667104 creator A5076453570 @default.
• W2024667104 creator A5077048802 @default.
• W2024667104 creator A5081650405 @default.
• W2024667104 creator A5086167544 @default.
• W2024667104 date "1999-04-01" @default.
• W2024667104 modified "2023-09-23" @default.
• W2024667104 title "Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group" @default.
• W2024667104 cites W1846828978 @default.
• W2024667104 cites W1918033056 @default.
• W2024667104 cites W1921877523 @default.
• W2024667104 cites W1938763320 @default.
• W2024667104 cites W1968274099 @default.
• W2024667104 cites W1972823960 @default.
• W2024667104 cites W1991413561 @default.
• W2024667104 cites W1992500421 @default.
• W2024667104 cites W2063355012 @default.
• W2024667104 cites W2097603260 @default.
• W2024667104 cites W2105365583 @default.
• W2024667104 cites W2136066688 @default.
• W2024667104 cites W2138205116 @default.
• W2024667104 cites W2147996630 @default.
• W2024667104 cites W2170012309 @default.
• W2024667104 cites W2267320788 @default.
• W2024667104 cites W2347016516 @default.
• W2024667104 cites W4234557007 @default.
• W2024667104 cites W4242925813 @default.
• W2024667104 cites W2019789714 @default.
• W2024667104 doi "https://doi.org/10.1002/(sici)1096-911x(199904)32:4<259::aid-mpo4>3.0.co;2-3" @default.
• W2024667104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10102019" @default.
• W2024667104 hasPublicationYear "1999" @default.
• W2024667104 type Work @default.
• W2024667104 sameAs 2024667104 @default.
• W2024667104 citedByCount "17" @default.
• W2024667104 countsByYear W20246671042012 @default.
• W2024667104 countsByYear W20246671042014 @default.
• W2024667104 crossrefType "journal-article" @default.
• W2024667104 hasAuthorship W2024667104A5006642512 @default.
• W2024667104 hasAuthorship W2024667104A5007689159 @default.
• W2024667104 hasAuthorship W2024667104A5009641229 @default.
• W2024667104 hasAuthorship W2024667104A5013300560 @default.
• W2024667104 hasAuthorship W2024667104A5016860157 @default.
• W2024667104 hasAuthorship W2024667104A5017179381 @default.
• W2024667104 hasAuthorship W2024667104A5019608958 @default.
• W2024667104 hasAuthorship W2024667104A5027751015 @default.
• W2024667104 hasAuthorship W2024667104A5029680324 @default.
• W2024667104 hasAuthorship W2024667104A5030491895 @default.
• W2024667104 hasAuthorship W2024667104A5031445323 @default.
• W2024667104 hasAuthorship W2024667104A5033607211 @default.
• W2024667104 hasAuthorship W2024667104A5035749444 @default.
• W2024667104 hasAuthorship W2024667104A5044016093 @default.
• W2024667104 hasAuthorship W2024667104A5048912989 @default.
• W2024667104 hasAuthorship W2024667104A5056441277 @default.
• W2024667104 hasAuthorship W2024667104A5062333360 @default.
• W2024667104 hasAuthorship W2024667104A5063523753 @default.
• W2024667104 hasAuthorship W2024667104A5064262008 @default.
• W2024667104 hasAuthorship W2024667104A5067407925 @default.
• W2024667104 hasAuthorship W2024667104A5069503102 @default.
• W2024667104 hasAuthorship W2024667104A5074414195 @default.
• W2024667104 hasAuthorship W2024667104A5076453570 @default.
• W2024667104 hasAuthorship W2024667104A5077048802 @default.
• W2024667104 hasAuthorship W2024667104A5081650405 @default.
• W2024667104 hasAuthorship W2024667104A5086167544 @default.
• W2024667104 hasConcept C121608353 @default.
• W2024667104 hasConcept C126322002 @default.
• W2024667104 hasConcept C141071460 @default.
• W2024667104 hasConcept C143998085 @default.
• W2024667104 hasConcept C2778461978 @default.
• W2024667104 hasConcept C2781059491 @default.
• W2024667104 hasConcept C2781107101 @default.
• W2024667104 hasConcept C2781413609 @default.
• W2024667104 hasConcept C2909962599 @default.
• W2024667104 hasConcept C71924100 @default.
• W2024667104 hasConcept C90924648 @default.
• W2024667104 hasConceptScore W2024667104C121608353 @default.
• W2024667104 hasConceptScore W2024667104C126322002 @default.
• W2024667104 hasConceptScore W2024667104C141071460 @default.

• next